SS-31 | 10 vials

SS-31 (Elamipretide), also known by its brand name Forzinity™, is a novel synthetic tetra-peptide that selectively targets the inner mitochondrial membrane . It was co-discovered by Dr. Peter W. Schiller at the IRCM and Dr. Hazel Szeto at Cornell University as part of the Szeto-Schiller (SS) peptide family .

Key Specifications:

• CAS Number: 736992-21-5

• Molecular Formula: C₃₂H₄₉N₉O₅

• Molecular Weight: 639.73 g/mol

• Sequence: H-D-Arg-Dmt-Lys-Phe-NH₂ (where Dmt = 2',6'-dimethyl-L-tyrosine)

• Purity: ≥95% (research grade)

• Appearance: White lyophilized powder

• Solubility: Soluble in water

• Storage: Store at -20°C; protect from light and moisture

Mechanism of Action: SS-31 targets the inner mitochondrial membrane and interacts with cardiolipin, a phospholipid essential for mitochondrial cristae structure and electron transport chain function . This interaction:

• Preserves mitochondrial cristae integrity

• Reduces mitochondrial reactive oxygen species (ROS) production

• Increases ATP synthesis

• Prevents mitochondrial depolarization and permeability transition pore formation

• Has no effects on normal mitochondria—only protects stressed/damaged mitochondria

• Recently identified mechanism involves phospholipid scramblase 3 (PLSCR3) as an essential mediator

Key Advantages Over Traditional Antioxidants:

• Superior mitochondrial targeting compared to natural antioxidants

• Overcomes bioavailability limitations of traditional mitochondrial-targeted compounds

• Low toxicity profile

Research Applications:

Regulatory Status:

• September 19, 2025: FDA approved Forzinity™ (elamipretide/SS-31) as the first-ever approved mitochondria-targeted therapeutic for the treatment of Barth syndrome

• Currently in Phase 3 clinical trials for primary mitochondrial myopathy and age-related macular degeneration

• FOR RESEARCH USE ONLY. Not for human use outside approved clinical applications.